Back to search

Article

Real-World Data on Neutralizing Antibody and Safety of COVID-19 Vaccine against SAR-CoV2 Wild Type and Omicron Variant in Solid Cancer Patients

2024-05-13

Abstract excerpt

Cancer patients, susceptible to severe COVID-19 outcomes, exhibit varied vaccine responses, particularly those who are receiving chemotherapy. This prospective cohort study enrolled 115 cancer patients, and data from 91 patients who received two doses of COVID-19 vaccines were analyzed. Blood was drawn at baseline, day 28, and 6 months post-second dose for neutralizing antibody analysis. The primary outcome was se...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f44bf00a-32b8-5aff-b099-1c07f8c48122
DOI
10.20944/preprints202405.0843.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Real-World Data on Neutralizing Antibody and Safety of COVID-19 Vaccine against SAR-CoV2 Wild Type and Omicron Variant in Solid Cancer PatientsDOI 10.20944/preprints202405.0843.v1
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE studySemantic proximity
Immune responses following third COVID-19 vaccination are reduced in patients with hematologic malignancies compared to patients with solid cancerSemantic proximity
Efficacy and longevity of immune response to 3 <sup>rd</sup> COVID-19 vaccine and effectiveness of a 4 <sup>th</sup> dose in severely immunocompromised patients with cancerSemantic proximity
Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity – a randomized clinical trialSemantic proximity
Immunogenicity of SARS-CoV-2 mRNA Vaccines in Patients with Cancer: Findings from an International Collaborative Cohort StudySemantic proximity
Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE studySemantic proximity
Immunogenicity of SARS-CoV-2 mRNA Vaccines in Patients with Cancer: Findings from an International Collaborative Cohort StudySemantic proximity
Immunogenicity and Omicron Neutralization Following a Third COVID-19 Vaccination in Solid Cancer Patients Previously Primed with Two Doses of Chadox1 Vaccine: A Prospective Cohort StudySemantic proximity
Seroprevalence study prior and post vaccination in Cancer patients in Principality of Andorra (COVONCO study)Semantic proximity
Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron EraSemantic proximity
Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelinesSemantic proximity
Cancer Therapy and Immunogenicity of COVID Vaccine – CANINE StudySemantic proximity
Select a neighboring publication to make it the new centre.